Glenmark Pharma News and Updates

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 1
Author: ICICI Securities Limited

Keep track of all breaking news on Glenmark Pharma from all sources in a single place.

Glenmark Pharmaceuticals Ltd.

09 Apr 2026, 12:19PM

2163.20

-0.27%

Glenmark receives USFDA approval for generic progesterone vaginal inserts

Business Standard

Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic version of progesterone vaginal inserts used in fertility treatments. The approval by the US Food and Drug Administration (USFDA) is for progesterone vaginal inserts of strength 100 mg, Glenmark Pharmaceuticals Ltd said in a regulatory filing. It has been determined by the USFDA to be bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin vaginal inserts, 100 mg of Ferring Pharmaceuticals Inc, it added. Glenmark's progesterone vaginal inserts 100 mg will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, the company said. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12 months ended February ..

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

27 Feb 2026

2163.20

-0.27%

Glenmark to launch generic sodium phosphates injection in US in April 2026

Business Standard

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2163.20

-0.27%

Broker's call: Glenmark Pharma (Add)

Business Line

Choice International

Glenmark Pharma has gained 57.18% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2163.20

-0.27%

Sustainability of cost curbs key to boost earnings growth

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark’s Q3FY26 revenue growth was led by India biz, while US growth was muted post adjusted for USD 18mn of milestone income. Gross margin was lower by 259bps YoY due to unfavourable product and geographical mix, though cost curbs drove 131bps expansion in EBITDA margin.

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2163.20

-0.27%

Glenmark Pharmaceuticals Results Earnings Call for Q3FY26

Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2163.20

-0.27%

Mixed quarter; domestic strengthens

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted largely in-line financial performance in 3QFY26. The quarterly performance was driven by a healthy revival in the domestic formulation (DF) business, out-licensing income related to ISB2001, and better performance in emerging markets.

Number of FII/FPI investors increased from 401 to 422 in Dec 2025 qtr.

Glenmark Pharmaceuticals Ltd.

27 Nov 2025

2163.20

-0.27%

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Business Line

The inspection was conducted at the company's manufacturing facility from June 9 to June 17, 2025, Glenmark Pharmaceuticals Ltd said in a statement

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharma gains 2% on positive US FDA inspection report; details here

Business Standard | 27 Nov 2025

Glenmark Pharmaceuticals Ltd.

25 Nov 2025

2163.20

-0.27%

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

Business Standard

The company has launched Nebzmart GFB Smartules and Glenmark Airz FB Smartules, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)